Table 2.
Effects of ferric carboxymaltose administration on iron parameters.
| All Patients (n = 98) | Pre-FCM | Post-FCM | 95% CI | p -Value * |
| Mean s-ferritin, μg/L n (pre/post) 1 = 87 |
48.4 | 175.0 | 126.6 (97.5, 135) | <0.001 |
| Mean s-iron, μg/L n (pre/post) 1 = 84 |
51.9 | 84.4 | 32.5 (28.5, 44) | <0.001 |
| Mean TSAT, % n (pre/post) 1 = 75 |
12.8 | 27.2 | 14.4 (11.6, 17) | <0.001 |
| Patients with CD (n = 66) | Pre-FCM | Post-FCM | 95% CI | p -Value * |
| Mean s-ferritin, μg/L n (pre/post) 1 = 56 |
44.7 | 175.0 | 130.3 (94.5, 142.5) | <0.01 |
| Mean s-iron, μg/L n (pre/post) 1 = 51 |
47.6 | 76.3 | 28.7 (22.0, 38.5) | <0.01 |
| Mean TSAT, % n (pre/post) 1 = 44 |
13.1 | 24.9 | 11.8 (11.6, 17.0) | <0.01 |
| Patients with UC (n = 32) | Pre-FCM | Post-FCM | 95% CI | p -Value * |
| Mean s-ferritin, μg/L n (pre/post) 1 = 28 |
56.4 | 174.8 | 118.4 (78.5, 154.0) | <0.01 |
| Mean s-iron, μg/L n (pre/post) 1 = 28 |
60.6 | 99.9 | 39.3 (33.5, 65.5) | <0.01 |
| Mean TSAT, % n (pre/post) 1 = 26 |
12.1 | 31.2 | 19.1 (11.6, 17.0) | <0.01 |
CI = confidence interval; CD = Crohn’s disease; FCM = ferric carboxymaltose; s-ferritin = serum ferritin; s-iron = serum iron; TSAT = transferrin saturation; UC = ulcerative colitis; 1 = Number of patients with laboratory values before and after FCM treatment; * = Wilcoxon signed-rank test.